RETEVMO® (selpercatinib) is an oral, highly selective kinase inhibitor specifically targeting rearranged during transfection (RET) gene alterations. It is available in both capsule and tablet formulations, with dosing regimens tailored according to patient age, body weight, or body surface area, and the presence of hepatic impairment. RETEVMO® is designed to inhibit aberrant RET signaling, which is implicated in the pathogenesis of certain cancers, including NSCLC, medullary thyroid cancer, and other RET fusion-positive solid tumors.

The clinical application of RETEVMO® is based on robust molecular diagnostics to identify eligible patients with RET gene fusions or mutations. Its efficacy and safety have been demonstrated in multiple clinical trials, leading to its approval for use in both adult and pediatric populations. RETEVMO® offers a targeted therapeutic option for patients with limited alternatives, particularly those with disease progression after standard therapies or with tumors refractory to conventional treatments.